MD Anderson and Yingli Pharma initiate strategic collaboration to advance development of multiple oncology programs
Â鶹ӳ» MD Anderson Cancer Center and Yingli Pharma US, Inc. today announced a strategic alliance to advance several oncology programs from preclinical discovery through clinical development.
The five-year collaboration brings together Yingli’s experience in medicinal chemistry with MD Anderson’s comprehensive clinical and translational resources to drive existing Yingli therapeutic candidates into four U.S...
Nano-sized vesicles with ACE2 receptor could prevent, treat infection from current and future strains of SARS-CoV-2
Scientists at Â鶹ӳ» MD Anderson Cancer Center and Northwestern Medicine have identified natural extracellular vesicles...
MD Anderson and Eisbach Bio announce strategic collaboration to develop medicines targeting epigenetic machinery in oncology
Â鶹ӳ» MD Anderson Cancer Center and Eisbach Bio GmbH today announced a strategic research collaboration to jointly discover...